Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy

被引：0
|
作者：
Qiaoyun Tan
Liyuan Dai
Yanrong Wang
Shuxia Liu
Te Liang
Rongrong Luo
Shasha Wang
Ning Lou
Haizhu Chen
Yu Zhou
Qiaofeng Zhong
Jianliang Yang
Puyuan Xing
Xingsheng Hu
Yutao Liu
Shengyu Zhou
Jiarui Yao
Di Wu
Zhishang Zhang
Le Tang
Xiaobo Yu
Xiaohong Han
Yuankai Shi
机构：
[1] Department of Medical Oncology,
[2] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,undefined
[3] Chinese Academy of Medical Sciences & Peking Union Medical College,undefined
[4] Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs,undefined
[5] State Key Laboratory of Proteomics,undefined
[6] Beijing Proteome Research Center,undefined
[7] National Center for Protein Sciences-Beijing (PHOENIX Center),undefined
[8] Beijing Institute of Lifeomics,undefined
[9] Clinical Pharmacology Research Center,undefined
[10] Peking Union Medical College Hospital,undefined
[11] State Key Laboratory of Complex Severe and Rare Diseases,undefined
[12] NMPA Key Laboratory for Clinical Research and Evaluation of Drug,undefined
[13] Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs,undefined
[14] Chinese Academy of Medical Sciences & Peking Union Medical College,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Anti-PD1/PDL1 lgG; Subclass; Anti-PD1 IgG4; Biomarker; Anti-PD1 therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1681 / 1691
页数：10
相关论文
共 50 条
  • [1] Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy
    Tan, Qiaoyun
    Dai, Liyuan
    Wang, Yanrong
    Liu, Shuxia
    Liang, Te
    Luo, Rongrong
    Wang, Shasha
    Lou, Ning
    Chen, Haizhu
    Zhou, Yu
    Zhong, Qiaofeng
    Yang, Jianliang
    Xing, Puyuan
    Hu, Xingsheng
    Liu, Yutao
    Zhou, Shengyu
    Yao, Jiarui
    Wu, Di
    Zhang, Zhishang
    Tang, Le
    Yu, Xiaobo
    Han, Xiaohong
    Shi, Yuankai
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1681 - 1691
  • [2] Distribution of anti-PD1/PDL1 autoantibodies in multiple cancer types and potential biomarker role for anti-PD1 therapy
    Tan, Q.
    Wang, Y.
    Liu, S.
    Luo, R.
    Wang, S.
    Liang, T.
    Yang, J.
    Xing, P.
    Yao, J.
    Wu, D.
    Zhang, Z.
    Dai, J.
    Yu, X.
    Han, X.
    Shi, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1097 - S1098
  • [3] Anti-PD1/PDL1 induced psoriasis
    Voudouri, D.
    Nikolaou, V.
    Laschos, K.
    Charpidou, A.
    Soupos, N.
    Triantafyllopoulou, I.
    Panoutsopoulou, I.
    Tsimpoukis, S.
    Aravantinos, G.
    Syrigos, K.
    Stratigos, A. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 53 - 54
  • [4] Anti-PD1/PDL1 induced psoriasis
    Voudouri, Dimitra
    Nikolaou, Vasiliki
    Laschos, Konstantinos
    Charpidou, Andriani
    Soupos, Nikolaos
    Triantafyllopoulou, Ioanna
    Panoutsopoulou, Ioanna
    Aravantinos, Gerasimos
    Syrigos, K.
    Stratigos, A.
    CURRENT PROBLEMS IN CANCER, 2017, 41 (06) : 407 - 412
  • [5] Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
    Lei, Qingyang
    Wang, Dan
    Sun, Kai
    Wang, Liping
    Zhang, Yi
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [6] Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
    Weidhaas, Joanne
    Marco, Nicholas
    Scheffler, Aaron W.
    Kalbasi, Anusha
    Wilenius, Kirk
    Rietdorf, Emily
    Gill, Jaya
    Heilig, Mara
    Desler, Caroline
    Chin, Robert K.
    Kaprealian, Tania
    McCloskey, Susan
    Raldow, Ann
    Raja, Naga P.
    Kesari, Santosh
    Carrillo, Jose
    Drakaki, Alexandra
    Scholz, Mark
    Telesca, Donatello
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
  • [7] Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
    Fazel, Mina
    Dufresne, Armelle
    Vanacker, Helene
    Waissi, Waisse
    Blay, Jean-Yves
    Brahmi, Mehdi
    CANCERS, 2023, 15 (06)
  • [8] Clinical analysis of patients (pts) with lung cancer treated with anti-PD1/PDL1 therapy
    Zhao, Xin
    Liu, Siyao
    Su, Junyan
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
    Luo, Kunpeng
    Liu, Shuqiang
    Shen, Xiuyun
    Xu, Jincheng
    Shi, Chunpeng
    Chao, Yuqiu
    Wen, Zhengchao
    Zhang, Kejiao
    Wang, Ru
    Liu, Bing
    Jiang, Yanan
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [10] Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.
    Eroglu, Zeynep
    Kim, Dae Won
    Johnson, Douglas Buckner
    Algazi, Alain Patrick
    Munhoz, Rodrigo Ramella
    Liniker, Elizabeth
    Kong, Ben
    Khurana, Neharika
    Chmielowski, Bartosz
    Sosman, Jeffrey Alan
    Scolyer, Richard A.
    Carlino, Matteo S.
    Postow, Michael Andrew
    Hwu, Wen-Jen
    Long, Georgina V.
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345